Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic-Ischemic Brain Injury in Neonatal Mice

ASN Neuro. 2023 Jan-Dec:15:17590914231198983. doi: 10.1177/17590914231198983.

Abstract

Neonatal hypoxia-ischemia reduces nicotinamide adenine dinucleotide (NAD+) and SIRT6 levels in the injured hippocampus.Hippocampal high mobility group box-1 (HMGB1) release is significantly increased after neonatal hypoxia-ischemia.Nicotinamide mononucleotide (NMN) treatment normalizes hippocampal NAD+ and SIRT6 levels, with significant decrease in caspase-3 activity and HMGB1 release.NMN improves early developmental behavior, as well as motor and memory function.

Keywords: alarmins; hypoxic–ischemic encephalopathy; infant; nicotinamide adenine dinucleotide; sirtuins; therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Brain Injuries* / drug therapy
  • HMGB1 Protein* / therapeutic use
  • Hypoxia
  • Ischemia
  • Mice
  • NAD / therapeutic use
  • Nicotinamide Mononucleotide / pharmacology
  • Nicotinamide Mononucleotide / therapeutic use
  • Sirtuins* / therapeutic use

Substances

  • Nicotinamide Mononucleotide
  • NAD
  • HMGB1 Protein
  • Sirtuins